Every year, thousands of women in Germany are diagnosed with breast cancer. According to the Robert Koch Institute, a total of 75,090 women in Germany were newly diagnosed with the disease in 2023. It becomes particularly dangerous when cancer cells affect the bone. In these cases, doctors speak of bone metastases.
How exactly this happens in the earliest stages has hardly been observed until now. Researchers led by Jana Sievers-Liebschner from the Leibniz Institute of Polymer Research Dresden (IPF), together with international partners, have now developed a new type of laboratory model that makes exactly this possible.
Less animal testing, faster therapies
The model is not only a tool for understanding. It can also be used to systematically test new drugs against metastases. Previously, this often required animal experiments. The new gel system offers a controllable alternative in the laboratory and could thus help to test active substances in a more targeted and faster way.
Jana Sievers-Liebschner conducted the research in close collaboration with Claudia Fischbach from Cornell University in New York and Peter Fratzl from the Max Planck Institute of Colloids and Interfaces in Potsdam. Bone metastases often develop early in the course of the disease, long before they are recognized. Those who understand these first steps better can intervene earlier. This opens up new perspectives for the development of targeted therapies against breast cancer in the bone.
Original publication:
Sievers-Liebschner et al. Mineralized Cryogel/Hydrogel Constructs to Recapitulate Early Breast Cancer Bone Metastasis In Vitro. Advanced Science (2025).